Announcement PDF ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113 AUSTRALIA TELEPHONE +61 2 8935 9629 WEB www.oncosil.com ASX Announcement 20 November 2025 OncoSil Medical to present at the 2025 Bell Potter Healthcare Conference Sydney, Australia – 20 November 2025: OncoSil Medical Limited (ASX: OSL) today announces an upcoming presentation by Mr Nigel Lange, CEO & Managing Director at the 2025 Bell Potter Healthcare Conference at 3.00pm AEDT today in Sydney, Australia. A copy of the presentation is attached. Authorisation & Additional Information This announcement was authorised by the Chairman of OncoSil Medical Limited. For further information, please contact: About OncoSil Medical OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical’s mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy. OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs. Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year1. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival. OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Greece, Turkey, and Israel. To learn more, please visit: www.oncosil.com/ 1. https://gco.iarc.fr/en Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043 Mr. Tim Luscombe & Mr. David Wood Joint Company Secretaries E: tim.luscombe@bio101.com david.wood@bio101.com T: +61 429 707 079 & +61 408 393 670 Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338 1 OncoSil Intratumoural placement of 32P for locally advanced pancreatic cancer Nigel Lange, 20 November 2025 Bell Potter Healthcare Conference 2025 Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the information contained should be read in conjunction with past and future ASX announcements made by OncoSil and should not be relied upon as an independent source of information. Please contact OncoSil and/or refer to the Company's website www.oncosil.com for further information. Not an Offer for Securities Nothing in this Presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in the Company, in any jurisdiction. This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act. The distribution of this presentation in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this presentation should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of law. Please refer to the international offer restrictions section of this presentation. This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or in any jurisdiction in which such offer would be illegal. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold , directly or indirectly, in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. Forward-Looking Statements This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales, nor that that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved. In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory requirements, our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined herein. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk. Disclaimer This Presentation and any supplemental materials have been prepared by OncoSil based on available information. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of OncoSil or any of its members, directors, officers, employees, or agents or corporate advisors, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of OncoSil or any of its directors, officers, employees or agents. The information contained in this presentation is current as at 19 November 2025. 2 Corporate Overview OncoSil Medical | 13 November 2025 GICS: Health Care – Pharmaceuticals, Biotechnology & Life Sciences (Life Sciences Tools & Services) ASX code: OSL Market cap: $24.7 million Shares on Issue: 18.83 million Share price: $1.31 (as at 13-Nov-25) 52-week high: $3.60 52-week low: $0.80 Average daily volume: 31,654 Free float: 66.2% Cash on Hand (30-Sep-25) $5.92 million 3 OncoSil Medical Major Shareholders | 13 November 2025 Washington H. Soul Pattinson (Pengana Capital Group Limited) 18.18% State Street Australia Ltd (Australian Ethical Investment Limited) 6.93% TOP 20 54.0% $0.90 $1.10 $1.30 $1.50 $1.70 $1.90 0 100,000 200,000 300,000 400,000 500,000 13-Jun-25 13-Jul-25 13-Aug-25 13-Sep-25 13-Oct-25 Share Price Performance Volume LHS Share Price ($) RHS Depth in Interventional Oncology and Nuclear Medicine Commercialisation Experienced Board and Management Dr Jon Bell MD Chief Medical Officer 12 years’ experience as consultant interventional radiologist and an internationally recognised expert in interventional oncology. Shelley Steyn Chief Financial Officer Extensive experience in senior accounting, commercial and financial analysis, and audit roles across listed and private companies. Dr Thomas Duthy Non-executive Chairman 20+ years of experience across financial markets, corporate development and board-level roles, involved in numerous successful M&A transactions. Nigel Lange Managing Director & CEO Executive Director 30+ years’ experience in medical device industry. Served as Group COO and Interim Group CEO of Sirtex Medical (ASX:SRX). Lel Smits Non-executive Director Award-winning entrepreneur, director and investor relations advisor, serving as a Director on Australian Shareholders’ Association since 2021. 4 Renzo DiCarlo Head of Transformation A proven nuclear medicine executive Renzo brings over 25 years’ experience in therapeutic drugs and medical devices. Recent Achievements 5 Completion of recruitment at PANCOSIL trial and data presented at CIRSE’25 Congress for novel percutaneous delivery Completion of recruitment at TRIPP-FFX trial for label expansion with additional chemotherapy - FOLFIRINOX Innovation funding approval (NUB status 1) across 120 German Hospitals Engagement with US FDA on Distal Cholangiocarcinoma dossier Fit-out completed for second manufacturing facility in Sydney, Australia First patient treatments at Germany and Portugal MDR Approval received with lifting of post-market restrictions German Federal Joint Committee (G-BA) tender in final stages for appointing CRO Commercialising targeted radiotherapy for pancreatic cancer • OncoSil Medical is commercialising the OncoSil device, an implanted device (brachytherapy) delivering targeted radiation (32P) to pancreatic tumours • OncoSil device is now approved for sale in over 34 countries via CE Mark • Commercial ramp-up has commenced in FY26, driven by significant growth in existing European markets • Increasing market access via label expansion combining new delivery methods and new chemotherapy combinations1 • Platform technology can be leveraged into other cancer indications (Bile duct cancer, liver, glioblastoma) • Experienced Board & Management team in the commercialisation of interventional oncology devices >US$4.2bn global addressable market with no competition3 • Granted Breakthrough designation in the EU, UK and US with extensive patent coverage across all key geographies • Large global pancreatic cancer patient population of ~510k p.a and targeting locally unresectable population of ~153k (~30%) with the market expected to increase by 37% by 20352 • Negligible survival improvement in over 20 years with <12% survival rates at 5-years and 8.5 months median overall • Patient recruitment completed for PANCOSIL & TRIPP-FFX trials, targeting:  Percutaneous delivery to drive market access and clinical adoption globally  Label expansion in addition to standard-of-care chemotherapy (FOLFIRINOX) Executive Summary References: 1. Subject to Regulatory Approval. 2. Globocan 2022 data . 3 179,000 global locally advanced pancreatic cancer population multiplied by US$24k average price 6 Significant achievements over CY25 • Received MDR Approval which includes the removal of all existing post-market restrictions (OSPREY registry) • Patient recruitment completed for PANCOSIL study and preliminary data presented at CIRSE 2025 Congress (a groundbreaking delivery method for OncoSil device) • Patient recruitment completed for TRIPP-FFX trial (to expand OncoSil device label with additional chemotherapy combination) • Second manufacturing facility in Sydney, Australia activated and ready to undergo validation. • Constructive discussions with US FDA on the regulatory pathway for OncoSil device in Bile Duct Cancer (dCCA) • German Federal Joint Committee (G-BA) tender process underway to appoint a CRO • First patient treatments completed at Germany and Portugal Catalyst rich CY25/26 • Strong commercial momentum and growing hospital adoption across existing markets: Austria, Germany, Greece, Israel, Italy, Portugal, Spain, Turkey, and the UK • Tender finalisations expected to drive significant revenue growth • Finalisation of G-BA tender process to appoint CRO and commence recruitment for the G-BA trial • Label expansion targeting: • Percutaneous delivery for Interventional Radiology (PANCOSIL study) • Combination with standard-of-care chemotherapy - FOLFIRINOX (TRIPP-FFX study) • First commercial production at Sydney manufacturing facility (H1 CY26) • Publication of real-world clinical data to support market access and drive adoption • Accelerating commercial activities through expanded market access and new geographic opportunities across the Nordics and MENA regions1 • TGA Approval – in review Executive Summary 7 References: 1. Subject to Regulatory Approvals. Pancreatic Cancer Prognosis has Remained Unchanged for 40 Years1 Changes in survival, 1971-72 to 2010-11 Incidence All Cancers Testis Malignant Melanoma Prostate Hodgkin Lymphoma Breast Uterus NHL Cervix Larynx Bowel Bladder Kidney Leukaemia Ovary Myeloma Stomach Brain Oesophagus Lung Pancreas 0% 25% 50% 75% 100% Survival rates are very poor: • 8.5 months overall median survival • <12% reach 5-year survival2 • Lower survival rate than any other cancer3 • The number of cases and deaths both estimated to increase by 40% before 20353 New therapeutic options urgently needed 8 References: 1. Cancer Research UK. www.cancerresearchuk.org/health-professional/cancer-statistics/survival/common-cancers-compared#heading-Three (accessed September 2024). 2. American Cancer Society. Cancer Facts & Figures 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023- cancer-facts-and-figures.pdf. 3. United European Gastroenterology. Pancreatic Cancer Across Europe: Taking a united stand. https://ueg.eu/files/771/b7ee6f5f9aa5cd17ca1aea43ce848496.pdf. Surgical resection remains the only potentially curative treatment for pancreatic cancer1 Pancreatic Cancer Stage at Diagnosis RESECTABLE 19 Surgical resection with curative intent Median OS Treatment % of patients at diagnosis 15% LOCALLY ADVANCED Palliative therapies (CT or ICT/CCRT)1,7,8,10 30% METASTATIC Palliative therapies (usually CT only)1,8 55% ~13 11.1 + <6 8.5 months [GEM]4 months [GEM-NP]5 months [FOLFIRINOX]6 months3,7 months2 30% of LAPC patients show metastatic progression within 3-6 months9,10 9 Abbreviations: CT: Chemotherapy; ICT: Induction chemotherapy; CCRT: Concurrent chemoradiation therapy. References: 1. Ducreux M et al. Ann Oncol 2015; 26 (Suppl 5): v56–68. 2. van Dam JL et al. Eur J Cancer. 2022; 160: 140–149. 3. Chang JS et al. Cancer Res Treat 2018; 50: 562–574 (suppl data). 4. Burris HA 3rd et al. J Clin Oncol 1997; 15: 2403–2413. 5. Von Hoff DD et al. N Engl J Med 2013; 369: 1691–1703. 6. Conroy T et al. N Engl J Med 2011; 364: 1817–1825. 7. Balaban EP et al. J Clin Oncol 2016; 34: 2654–2668. 8. National Comprehensive Cancer Network (NCCN) Clinical Practive Guidelines in Oncology: Pancreatic adenocarcinoma. Version 1.2020. 9. Huguet et al. J Clin Oncol 2010. 10. Mukherjee et al, Lancet Oncol 2013. OncoSil Device OncoSil is intended for the treatment of locally advanced unresectable pancreatic cancer, in addition to gemcitabine-based chemotherapy (combination with FOLFIRINOX currently in trials) OncoSil is a single-use brachytherapy device comprised of microparticles and a diluent OncoSil is currently implanted directly into a pancreatic tumour via injection under endoscopic ultrasound guidance 98% of all radiation is delivered within 81 days of injection causing damage to cancer cell DNA and killing malignant cancer cells with no damage to surrounding tissue Percutaneous delivery is transformational and anticipated to significantly accelerate market penetration:  Expanding the number of treating clinicians to include Interventional Radiologists  Broader patient access and points of care  Outpatient day procedure – complete within 20 minutes  Conscious sedation (patient awake) Patient recruitement at PANCOSIL study completed and preliminary data presented at CIRSE 2025 Congress Targeting H2 CY26 to make OncoSil commercially available to Interventional Radiologists Requires only one supervised procedure given simplicity and familiarity with standard, everyday, biopsy procedures Driving increased resection rates, downstaging, survival benefits and quality of life 10 4 clinical studies supporting commercialisation demonstrate efficacy, safety and tolerability in LAPC Growing Body of Evidence Unresectable Locally Advanced Pancreatic Cancer (LAPC) Unresectable LAPC or Borderline-Resectable LAPC Metastatic PDAC Study PanCO Study 1 OncoPaC-1 Study2 Propensity Score Weighted Landmark Analysis 3 Comparative Analysis 4 Metastatic Study 5 Treatment OncoSil + Chemotherapy a OncoSil + gemcitabine/ nab-paclitaxel OncoSil + Chemotherapy b Chemotherapy b (± Chemoradiotherapy) OncoSil + Chemotherapy b Chemotherapy b + SBRT OncoSil + Chemotherapy a Sample Size 42 (50 ITT) 9 50 35 at landmark 54 51 at landmark 42 59 14 Local Disease Control Rate at 16 weeks 90.5% 77.8% nr nr nr nr 100% Objective Response Rate 31.0% 22.2% nr nr nr nr 57.1% Disease Control Rate 100% 100% nr nr nr nr 100% Surgical Resection with Curative Intent 23.8% 0 28.6% 12.1% 22% 0% 7.1% Downstaging 33.3% not reported 31.4% 13.6% 23.8% 3.4% 7.1% Local PFS, median 9.8 months 27.3 months 15.6 months 9.3 months 18.9 months 14.1 months 12.2 months Distant PFS or PFS (PFS), median 9.3 months PFS 12.2 months PFS 14.2 months 10.7 months 20.0 months 14.0 months 9.2 months PFS Overall Survival, median 15.5 months 27.3 months 20.0 months 12.3 months 22 months 14 months 13.8 months p=0.002 p=0.006 p=0.03 p=0.03 p=0.058 vs. p<0.001 p=0.003 HR 0.62 p=0.040 HR 0.59 p=0.023 HR 0.45 p=0.014 vs. 11 Key: a Gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy; b gemcitabine/nab-paclitaxel, gemcitabine or FOLFIRINOX chemotherapy; Abbreviations: LAPC, locally advanced pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; PFS, progression-free survival. Use of OncoSil for borderline-resectable LAPC or metastatic pancreatic ductal adenocarcinoma (mPDAC) is off-label. References: 1. Ross PJ et al. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/ nab-paclitaxel or FOLFIRINOX chemotherapy. ESMO Open February 2022; 7 (1): 100356. 2. OncoSil Medical Ltd. Data on file. 3. Lim A et al. Combined phosphorus-32 implantation and chemotherapy alone for locally advanced pancreatic cancer: a propensity-score weighted landmark analysis. Gastrointest Endosc 2025 May 8. 4. Lim A et al. Comparison of combined chemotherapy and stereotactic body radiation therapy with combined chemotherapy and phosphorus-32 microparticle intra-tumoural implantation in patients with locally advanced pancreatic adenocarcinoma. Presented at Digestive Disease Week (DDW2025) scientific meeting in San Diego, USA, 3–6 May 2025. 5. Lim A et al. Outcomes of phosphorus-32 microparticle intratumoral implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinoma. iGIE 2024 July 2; ePub 1–9. Significant Commercial Opportunity Existing Priority Markets Target Market Pancreatic Cancer Incidence p.a.1 Locally Advanced Pancreatic Cancer2 Market Opportunity (A$m)3 UK 11,852 3,556 138 Spain 9,282 2,785 108 Italy 16,111 4,833 188 Germany 22,587 6,776 264 Greece 2,343 703 27 Austria 2,250 675 26 Turkiye 9,012 2,704 105 Portugal 2,217 665 26 Israel 1,249 375 15 Total (Existing) 76,903 23,071 898 Near-Term Target Markets South Korea 10,046 3,014 117 France 16,538 4,961 193 Denmark 1,454 436 17 Finland 1,570 471 18 Norway 1,275 383 15 Switzerland 2,056 617 24 Saudi Arabia 666 200 8 Hong Kong 1,116 335 13 Netherlands 3,689 1,107 43 Belgium 2,433 730 28 Total (New) 40,843 12,253 477 OncoSil device remains at the early- stage of commercialization in existing geographies with ~A$898m market size Expanding to ~A$1,375m addressable market over next 18 –24 months Market Penetration expected to now accelerate over the near-term driven by:  Percutaneous Delivery following a target H2 CY26 label expansion  Commencement of Patient Recruitment for the G-BA Trial 12 Reference: 1. Globocan 2025 data. 2 Calculated as 30% of Pancreatic Cancer Incidence. 3 Local Price in EUR converted to AUD (EURAUD) 1.77 Accelerating Commercialisation Enhancing market access via label extension 13 Program Description Key Milestones Commercial Impact PANCOSIL Feasibility and safety of CT-guided percutaneous radionuclide therapy with OncoSil device + Chemotherapy in non-progressive locally advanced pancreatic cancer • Patient recruitment completed • Initial results were presented at CIRSE 2025 • Regulatory submission target of Q1 CY26 – Added to Label and targeted commercial launch in EU and UK markets in H2 CY26 Accelerates market penetration with lower barriers to adoption via a new method of delivery for a new medical speciality (Interventional Radiology) TRIPP-FFX Efficacy and Safety of Oncosil combined with standard FOLFIRINOX chemotherapy vs. FOLFIRINOX chemotherapy alone • Patient recruitment completed • Results expected at H1 CY26 • Target Regulatory submission H2 CY26 • Added to Label in all approved jurisdictions H2 CY26 Accelerates market penetration with label expansion to include coverage of OncoSil device in addition to standard-of-care chemotherapy (FOLFIRINOX) Bile Duct Cancer Bile Duct Cancer (Distal Cholingiocarcinoma - dCCA) For approval by US FDA under Human Device Exemption (HDE) • Discussions remain ongoing and constructive with US FDA • OncoSil submitted additional data to support HDE application Small addressable market however a supportive pathway to US market entry for LAPC 13 Commercial significance of G-BA Trial and beyond Unlocking Market Potential in Germany 14 G-BA approval received Oct-24 Tender process for CRO started in May-25 Expecting first treatment in G-BA trial in H1 CY26 First patient treatment at Germany in Oct-25 (outside of trial)  Public insurance reimbursement for OncoSil device in Germany for trial participants  Opportunity to participating hospitals to receive reimbursement for patients not participating in trial  5 hospitals already received positive decision from public health funds to start OncoSil treatments before G-BA trial starts Opportunity to open 20 additional sites before start of G-BA trial Commercial significance of G-BA Trial and beyond Unlocking Market Potential in Germany The top 50 German pancreatic cancer centers performed approximately 5,000 complex pancreatic surgeries in 20241, accounting for 43% of all such procedures nationwide. These high-volume centers represent our primary targets for commercial adoption, alongside their anticipated participation in the G-BA trial2. 15 References: 1. https://www.aok.de/pp/hintergrund/mindestmengen/mindestmengen-transparenzkarte-2026/ 2. The centers with appropriate nuclear medicine facilities capable of delivering OncoSilTM device. 583 212 171 150 148 148 143 142 142 139 126 124 113 102 98 96 93 92 82 82 0 100 200 300 400 500 600 700 Complex Pancreatic Surgeries in 2024 Accelerating growth in existing territories Unlocking Market Potential in Europe Country Key Milestones Commercial Importance Spain • OncoSil available in 11 hospitals • 6 hospitals routinely ordering and treating with OncoSil • Over 70 patients treated with OncoSil device until now • Largest revenue-contributing market • Strong referral acceptance from oncologists and surgeons • Strong growth in usage and revenue Italy • 5 hospitals routinely ordering and treating with OncoSil • First tender agreement signed, further tenders to be finalized in Q1 CY26 • OncoSil adopted by two leading hospitals — University of Verona and San Camillo Forlanini Hospital • Revenue contribution expected to increase significantly in H1 CY26 following finalisation of individual tender agreements Greece • 1 hospital routinely ordering and treating with OncoSil • Training underway at 2 additional hospitals • Significant revenue contributor despite small population size • Intention to publish local real-world data Israel • 1 hospital routinely ordering and treating with OncoSil • Training underway at 2 additional hospitals • OncoSil approved by Clalit Health Services — second largest health insurer in Israel • Despite logistical challenges, treatment well accepted by key opinion leaders (KOLs) and integrated in clinical practice Turkey • 3 hospitals routinely ordering and treating with OncoSil • Training completed at 6 hospitals; first patient treatments pending • 45% resection rate in real-world setting • One of the largest potential markets in oncology and nuclear medicine treatments • Ongoing referral education initiatives to increase patient flow 16 Commercial ramp up with upside expected from new market access initiatives Outlook 17 Unit volumes are expected to ramp up materially following onboarding activities in existing initial markets in CY26 Volumes in existing markets are expected to underpin growth from market entry expectations over the near-term OncoSil has an aspirational target of 5–10% market penetration in existing and near-term target markets implying up to 3,532 units p.a. Label expansion activities enhancing market access including: • Percutaneous delivery method for new clinician group (Interventional Radiologists); and • Combination with FOLFIRINOX chemotherapy This is provided for illustrative purposes only. It is not a forecast nor is there any guarantee that the market penetration, unit sale pricing or sales volume could or will be achieved. It also assumes regulatory product approvals which have not been obtained. As illustrative - it should not be relied upon in making an investment decision. Market Penetration 5% 7.5% 10% Units 1,766 2,649 3,532 Revenue (A$m) 69 103 138 Significant catalysts over the next 12 months Upcoming Milestones 18 First commercial dose supply from Sydney, Australia facility Regulatory submission for percutaneous application References: 1. Indicated in Distal Cholingiocarcinoma. 2. Subject to regulatory Review. 3. Subject to approval following PANCOSIL study. Q1 CY2026 Q2 CY2026 Finalisation of GBA trial design Review of real-world data from OSPREY registry Recruitment starts in G-BA trial Regulatory submission for label expansion to include FOLFIRINOX Q3 CY2026 Q4 CY2026 First OncoSil treatment at France Expansion of label to include FOLFIRINOX chemotherapy Label expansion to include Percutaneous Delivery Application for HAS/FORFAIT Innovation in France Completion of regulatory processes and launch in MENA Results of TRIPP-FFX trial Macquarie Cyclotek site Technology & Innovation 19  Macquarie Operations in process of final validation (95% complete) – completion target Q1 CY26  New Target from ANSTO being used in the validation with more capacity, quality and versatility. Quartz Ampoule from Mo-Sci fully implemented.  The site is ready to receive, process and measure Hot Target.  New dispensing doses of 50, 100, 150 and 250 Mbq are being validated for therapy.  Cyclotek ISO 13485 process have started – completion target H1 2026.  The R&D target schedule has been developed with ANSTO, Lucas Heights. ANSTO has agreed to increase reactor spots to meet growing demand. Nigel Lange CEO & M